The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis

INTRODUCTION: The dipeptidyl peptidase-4 inhibitor (DPP-4i) drugs, such as evogliptin, as the second-line drugs for type 2 diabetes mellitus (T2DM) treatment have been reported to facilitate insulin secretion by reducing glucagon and inhibiting glucagon like peptides. With a vague consensus, the adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Qizhi, Pan, Weiyu, Peng, Liangyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437312/
https://www.ncbi.nlm.nih.gov/pubmed/36060938
http://dx.doi.org/10.3389/fendo.2022.962385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437312/
https://www.ncbi.nlm.nih.gov/pubmed/36060938
http://dx.doi.org/10.3389/fendo.2022.962385

Ejemplares similares